Safety and efficacy of topical steroid administration in patients undergoing mandibular horizontal impacted wisdom tooth extraction

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs071210140

Enrollment

246

Registered

2022-03-28

Start date

2022-03-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mandibular horizontal impacted wisdom tooth mandibular horizontal impacted wisdom tooth

Interventions

Intervention group: Insert of Solu-Cortef penetrated Spongel for post-extraction tooth socket, and close the wound Control group: Insert of Spongel for post-extraction tooth socket, and close the woun

topical steroid administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. patients who are planned to undergo mandibular horizontal impacted wisdom tooth extraction 2. Patients who can personally provide written consent at their own free will after being receiving a thorough explanation of the study and fully understanding their participation in the study.

Exclusion criteria

Exclusion criteria: Any of the following patients will be excluded: 1. Patients with problem in judgement. 2. Patients receiving therapies with anti-resorption drugs. 3. Patients with a history of radiation therapy to the jawbone. 4. Patients are immunocompromised with steroid or immunosuppressants. 5. Patients receiving therapies with antithrombotic therapy. 6. Patients for whom administration of Sol-Corteph, Spongel, Amoxicillin, Loxoprofen Sodium Hydrate or Acetaminophen is contraindicated. 7. Patients receiving therapies with Desmopressin Acetate Hydrate 8. Patients who receive analgesics for pain at least once a week (e.g., cancer pain, non-cancer pain). However, topical analgesics and anti-inflammatory drugs (patches and applications) are allowed. 9. Women who are or may be pregnant or lactating women. 10. Partients who are judged to be inappropriate to participate the study by the principal or cooperative doctors.

Design outcomes

Primary

Measure	Time frame
postoperative pain (VAS)	—

Secondary

Measure	Time frame
number of uses of analgesic drug mental nerve hypoesthesia lingual nerve hypoesthesia trismus swelling dry socket SSI adverse study-drug event	—

Contacts

Public ContactTomofumi Naruse

Nagasaki University Hospital

naruse12@nagasaki-u.ac.jp+81-95-819-7698

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026